• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国人群种族、民族和年龄差异与肝内胆管癌发病和生存的关系:1995-2014 年。

Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014.

机构信息

Department of Health Sciences Research.

Department of Transplantation Mayo Clinic, Jacksonville, Florida, United States.

出版信息

Ann Hepatol. 2018;17(4):604-614. doi: 10.5604/01.3001.0012.0929.

DOI:10.5604/01.3001.0012.0929
PMID:29893702
Abstract

INTRODUCTION AND AIM

Despite reports of increased incidence of intrahepatic cholangiocarcinoma (iCCA) in the United States, the impact of age or influences of race and ethnicity are not clear. Disparities in iCCA outcomes across various population subgroups also are not readily recognized due to the rarity of this cancer. We examined ethnic, race, age, and gender variations in iCCA incidence and survival using data from the Surveillance, Epidemiology, and End Results Program (1995-2014).

MATERIAL AND METHODS

We assessed age-adjusted incidence rates, average annual percentage change in incidence, and hazard ratios (HRs) with 95% confidence intervals (CIs) for all-cause and iCCA-specific mortality.

RESULTS

Overall, 11,127 cases of iCCA were identified, with an age-adjusted incidence rate of 0.92 per 100,000. The incidence rate increased twofold, from 0.49 per 100,000 in 1995 to 1.49 per 100,000 in 2014, with an average annual rate of increase of 5.49%. The iCCA incidence rate was higher among persons age 45 years or older than those younger than 45 years (1.71 vs. 0.07 per 100,000), among males than females (0.97 vs. 0.88 per 100,000) and among Hispanics than non-Hispanics (1.18 vs. 0.89 per 100,000). Compared to non-Hispanics, Hispanics had poorer 5-year allcause mortality (HR = 1.11, 95%CI: 1.05-1.19) and poorer iCCA-specific mortality (HR = 1.15, 95%CI: 1.07-1.24). Survival rates were poor also for individuals age 45 years or older, men, and Blacks and American Indians/Alaska Natives.

CONCLUSION

The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States.

摘要

简介和目的

尽管有报道称美国肝内胆管癌(iCCA)的发病率有所增加,但年龄的影响或种族和民族的影响尚不清楚。由于这种癌症较为罕见,因此也不容易认识到不同人群亚组中 iCCA 结局的差异。我们使用美国监测、流行病学和最终结果计划(1995-2014 年)的数据,研究了 iCCA 发病率和生存率的种族、民族、年龄和性别差异。

材料和方法

我们评估了所有原因和 iCCA 特异性死亡率的年龄调整发病率、发病率的平均年变化百分比以及风险比(HR)及其 95%置信区间(CI)。

结果

共发现 11127 例 iCCA 病例,年龄调整发病率为 0.92/100000。发病率增加了两倍,从 1995 年的 0.49/100000 增加到 2014 年的 1.49/100000,平均年增长率为 5.49%。45 岁或以上人群的 iCCA 发病率高于 45 岁以下人群(1.71 比 0.07/100000),男性高于女性(0.97 比 0.88/100000),西班牙裔高于非西班牙裔(1.18 比 0.89/100000)。与非西班牙裔相比,西班牙裔的 5 年全因死亡率较差(HR = 1.11,95%CI:1.05-1.19),iCCA 特异性死亡率较差(HR = 1.15,95%CI:1.07-1.24)。45 岁或以上人群、男性和黑人和美国印第安人/阿拉斯加原住民的生存率也较差。

结论

结果表明,iCCA 的发病率和生存率存在种族、民族、年龄和性别差异,并证实美国 iCCA 的发病率持续增加。

相似文献

1
Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014.美国人群种族、民族和年龄差异与肝内胆管癌发病和生存的关系:1995-2014 年。
Ann Hepatol. 2018;17(4):604-614. doi: 10.5604/01.3001.0012.0929.
2
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.美国原发性肝内胆管癌的发病率和死亡率不断上升。
Hepatology. 2001 Jun;33(6):1353-7. doi: 10.1053/jhep.2001.25087.
3
Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.美国肝内胆管癌流行病学中的种族和民族差异。
Liver Int. 2006 Nov;26(9):1047-53. doi: 10.1111/j.1478-3231.2006.01350.x.
4
Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.美国肝内胆管细胞癌与肝细胞癌的临床特征和结局比较。
Hepatology. 2021 Nov;74(5):2622-2632. doi: 10.1002/hep.32007. Epub 2021 Sep 25.
5
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.美国 2001 至 2017 年胆管癌发病率和死亡率的时间变化。
Oncologist. 2022 Oct 1;27(10):874-883. doi: 10.1093/oncolo/oyac150.
6
Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends.胆管癌的流行病学;美国的发病率和死亡率趋势。
Clin Res Hepatol Gastroenterol. 2020 Nov;44(6):885-893. doi: 10.1016/j.clinre.2020.03.024. Epub 2020 Apr 28.
7
Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.肝外和肝内胆管癌转移和生存的分析:一项大型基于人群的研究。
Medicine (Baltimore). 2021 Apr 23;100(16):e25635. doi: 10.1097/MD.0000000000025635.
8
Racial and Ethnic Disparities in the Incidence of Pediatric Extracranial Embryonal Tumors.儿科颅外胚胎性肿瘤发病的种族和民族差异。
J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx050.
9
Increased risk for colorectal cancer under age 50 in racial and ethnic minorities living in the United States.在美国生活的少数族裔中,50岁以下人群患结直肠癌的风险增加。
Cancer Med. 2015 Dec;4(12):1863-70. doi: 10.1002/cam4.560. Epub 2015 Oct 16.
10
Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.美国国家癌症研究所监测、流行病学和最终结果(SEER)项目 1990 年至 2010 年的数据显示,主要癌症患者的生存率在种族、年龄和性别方面存在差异。
JAMA Oncol. 2015 Apr;1(1):88-96. doi: 10.1001/jamaoncol.2014.161.

引用本文的文献

1
Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database.种族对胆管癌入院情况、临床结局及出院处置的影响:来自全国住院患者数据库的见解
Diseases. 2025 Jul 4;13(7):211. doi: 10.3390/diseases13070211.
2
Intrahepatic cholangiocarcinoma mortality in the USA, 1999-2020: a 21-year population-based analysis.1999 - 2020年美国肝内胆管癌死亡率:一项基于21年人口的分析。
Cancer Causes Control. 2025 Jul 24. doi: 10.1007/s10552-025-02038-8.
3
Global burden of early-onset gallbladder and biliary tract cancer from 1990 to 2021.
1990年至2021年早发性胆囊癌和胆管癌的全球负担
BMC Gastroenterol. 2025 Jul 1;25(1):461. doi: 10.1186/s12876-025-04080-x.
4
Forty-five-year trends in intra- and extrahepatic cholangiocarcinoma: sex- and race-based insights.肝内和肝外胆管癌的45年趋势:基于性别和种族的见解
Ann Gastroenterol. 2025 Mar-Apr;38(2):214-220. doi: 10.20524/aog.2025.0951. Epub 2025 Feb 28.
5
An Examination of Liver Cancer Incidence in California.加利福尼亚州肝癌发病率调查
J Registry Manag. 2024 Winter;51(4):136-145.
6
Non-targeted effects of stereotactic radiotherapy: a review of the evidence coming from the clinical field.立体定向放射治疗的非靶向效应:来自临床领域证据的综述
Explor Target Antitumor Ther. 2025 Feb 13;6:1002290. doi: 10.37349/etat.2025.1002290. eCollection 2025.
7
Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.肝内胆管癌中年龄与肿瘤分期的相互作用:基于监测、流行病学和最终结果(SEER)分析的预后因素、死亡率趋势及治疗意义
Diseases. 2025 Jan 25;13(2):31. doi: 10.3390/diseases13020031.
8
Trends and Disparities in Intrahepatic Cholangiocarcinoma-related Mortality in the United States from 1999 to 2020.1999年至2020年美国肝内胆管癌相关死亡率的趋势与差异
J Gastrointest Cancer. 2025 Jan 27;56(1):53. doi: 10.1007/s12029-024-01132-5.
9
Assessing the value of computed tomography (CT) of the chest in the follow-up of patients with intrahepatic cholangiocarcinoma.评估胸部计算机断层扫描(CT)在肝内胆管癌患者随访中的价值。
J Gastrointest Oncol. 2024 Dec 31;15(6):2656-2662. doi: 10.21037/jgo-24-365. Epub 2024 Dec 28.
10
Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids.通过患者来源的类器官探索肠道微生物群对胆管癌进展的影响。
J Transl Med. 2025 Jan 9;23(1):34. doi: 10.1186/s12967-024-06012-x.